Does Verzenio (abemaciclib) cause renal failure?

Does Verzenio Cause Renal Failure?

Verzenio (abemaciclib) does not typically cause true renal failure, but it commonly causes a reversible, non-injurious increase in serum creatinine through inhibition of renal tubular creatinine transporters—a phenomenon known as "pseudo-renal failure." However, true acute kidney injury can occur, particularly in the context of severe dehydration from gastrointestinal toxicity or, rarely, from acute interstitial nephritis or acute tubular necrosis 1, 2, 3.

Understanding the Mechanism

Abemaciclib inhibits renal tubular transporters including organic cation transporter 2 (OCT2), multidrug and toxin extrusion protein (MATE) 1, and MATE2-K, which suppress creatinine secretion without causing actual kidney damage 1, 4. This leads to:

• Elevated serum creatinine without true renal injury
• Decreased calculated eGFR that does not reflect actual kidney function
• Reversible changes that return to baseline after drug discontinuation 4, 5

Clinical Impact and Incidence

Real-world data demonstrates significant effects on creatinine-based measurements:

• 30.8% of patients develop grade ≥2 creatinine elevation at 1 month, increasing to 56.6% after 2 years 4
• 50.2% of patients experience a change in renal function classification based on creatinine clearance 4
• 17.2% of patients show eGFR decreases ≥20 mL/min 5
• Median creatinine clearance drops from 61.6 to 44.5 mL/min during treatment 4

True Renal Injury: Less Common but Serious

While pseudo-renal failure is the predominant pattern, genuine kidney injury does occur:

Dehydration-Related Renal Failure

• 48% of renal adverse events with abemaciclib occur in the context of dehydration 2
• Predominantly associated with severe gastrointestinal toxicity (diarrhea, nausea, vomiting)
• Most cases are serious and require hospitalization 2

Intrinsic Kidney Injury

French pharmacovigilance data identified 42 cases of renal adverse events, with confirmed pathology showing 2, 3:

• Acute tubular necrosis (ATN)
• Acute interstitial nephritis (AIN)—can occur even after short-term use
• Three cases required renal replacement therapy 2
• One case of biopsy-proven AIN developed shortly after initiation with severe dysfunction (creatinine 15.16 mg/dL) and nephromegaly 3

Critical Management Algorithm

1. Distinguish Pseudo-Renal Failure from True Injury

When creatinine rises on abemaciclib, evaluate:

• Volume status: Assess for dehydration from diarrhea/vomiting
• Urinalysis: Check for proteinuria, hematuria, pyuria
• Renal tubular markers: Elevated markers suggest true injury
• Imaging: Nephromegaly on ultrasound suggests interstitial nephritis 3
• Cystatin C-based eGFR: This bypasses tubular secretion and provides accurate assessment 4, 5

2. Use Cystatin C for Accurate Assessment

The major pitfall: In clinical practice, cystatin C measurements are performed in only 4.2% of patients despite being essential for distinguishing pseudo-renal failure from true injury 5. Always obtain cystatin C-based eGFR when creatinine rises to avoid unnecessary dose modifications of abemaciclib or concomitant medications.

3. Manage Concomitant Medications Carefully

22.6% of patients require dose adjustments of renally-excreted concomitant medications due to creatinine-based eGFR changes 4. This can lead to:

• Inappropriate dose reductions of necessary medications
• Potential underdosing of critical therapies

Use cystatin C-based eGFR, not creatinine-based calculations, to guide dosing of concomitant renally-excreted drugs.

4. When to Suspect True Renal Injury

Red flags requiring renal biopsy consideration:

• Persistent creatinine elevation despite adequate hydration
• Nephromegaly on imaging 3
• Elevated renal tubular damage markers
• Proteinuria or active urinary sediment
• Systemic symptoms (fever, rash, eosinophilia)

5. Treatment of Confirmed Renal Injury

For biopsy-proven interstitial nephritis:

• Discontinue abemaciclib immediately
• Initiate glucocorticoid therapy 3
• Provide supportive care with fluid replacement
• Most cases show favorable outcomes with treatment 2, 3

For dehydration-related renal failure:

• Aggressive fluid replacement
• Manage gastrointestinal symptoms with antidiarrheals and antiemetics 6
• Consider temporary drug interruption
• Resume at reduced dose once renal function stabilizes

Key Clinical Pearls

• Abemaciclib discontinuation was required in 85% of true renal injury cases, with favorable outcomes in the majority 2
• Positive rechallenge occurred in 4 cases, including 2 with true acute kidney injury, suggesting caution with reintroduction 2
• Creatinine values return to baseline after abemaciclib discontinuation in pseudo-renal failure 4
• Female patients aged ≥46 years taking the drug ≥30 days represent the highest-risk demographic 7

Bottom Line

Verzenio causes pseudo-renal failure frequently through creatinine transporter inhibition, but true renal failure—while less common—can be severe and includes ATN and AIN. The critical error in practice is relying solely on creatinine-based eGFR without obtaining cystatin C measurements, leading to inappropriate medication adjustments. When creatinine rises, obtain cystatin C-based eGFR, assess volume status and urinalysis, and maintain high suspicion for true injury if clinical features suggest intrinsic kidney disease requiring biopsy and potential glucocorticoid therapy.